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ABSTRACT
The diagnosis and monitoring of myelodysplastic syndromes (MDS) are highly reliant on bone marrow morphology, which is associated with substantial interobserver variability. Azacitidine is the mainstay of treatment in MDS, however only half of all patients respond. Therefore, there is an urgent need for improved modalities for the diagnosis and monitoring of MDS. The majority of MDS patients have either clonal somatic karyotypic abnormalities and/or gene mutations that aid in the diagnosis and can be used to monitor treatment response. Circulating cell free DNA is primarily derived from haematopoietic cells, and we surmised that the malignant MDS genome would be a major contributor to cell free DNA levels in MDS patients as a result of ineffective haematopoiesis. Through analysis of serial bone marrow and matched plasma samples (n = 75) we demonstrate that cell free circulating tumour DNA (ctDNA) is directly comparable to bone marrow biopsy in representing the genomic heterogeneity of malignant clones in MDS. Remarkably, we demonstrate that serial monitoring of ctDNA allows concurrent tracking of both mutations and karyotypic abnormalities throughout therapy and is able to anticipate treatment failure. These data highlight the role of ctDNA as a minimally invasive molecular disease monitoring strategy in MDS.
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INTRODUCTION
Current diagnostic and prognostic algorithms in myelodysplastic syndromes (MDS) rely heavily on peripheral blood (PB) counts and bone marrow (BM) morphology [1] [2] [3] , which often has inter-observer variability 4 . Recurrent chromosomal aberrations have helped refine current MDS prognostic models 1, 2, 5 and more recently, the sequencing of MDS cancer genomes has also identified several recurrent mutations [6] [7] [8] [9] [10] [11] [12] which give prognostic insights at diagnosis 7, 8, [11] [12] [13] [14] [15] . However, there is little evidence of how the clonal and subclonal architecture is influenced by therapy.
Hypomethylating agents such as azacitidine and decitabine remain the mainstay of MDS treatment 16, 17 . However, response may take months to achieve and only half respond to therapy 18 . Repeated BM biopsies to monitor response can be invasive, associated with procedure-related complications, and resource demanding. These limitations have, in part, compromised our ability to more regularly assess response to therapy and study clonal evolution in MDS. In this regard, we assessed the role of cell free circulating tumor DNA (ctDNA) as a novel and minimally invasive biomarker to monitor therapeutic response and clonal evolution in MDS.
METHODS
Serial BM (n=89) and plasma samples (n=83) were collected from 12 patients with MDS that received azacitidine and eltrombopag as part of a phase 1 clinical trial (Table 1) . Targeted deep sequencing (TS) was performed on DNA derived from BM and plasma using a customised panel of 55 genes known to be recurrently mutated in MDS/AML (Supplemental Table 1 ). Sequencing of BM samples identified putative driver mutations in 10 of 12 patients ( Figure  1A ). Digital PCR (dPCR) was performed to validate the TS results. Quantification of mutant allele fraction (MAF) showed excellent correlation (Supplemental Figure 1A) between TS and dPCR.
Further methods are detailed in Supplemental Methods.
RESULTS AND DISCUSSION
ctDNA accurately reflects the fractional abundance of somatic mutations detected in bone marrow.
The majority of cell free DNA is derived from haematopoietic cells 19 . As MDS is a clonal disorder characterised by ineffective haematopoiesis, we postulated that the malignant MDS genome would be well represented in circulating cell free DNA. We first sought to understand how mutation detection in ctDNA compared to other haematopoietic compartments in a patient with MDS without significant cytopenia ( Figure 1B) . Here, the MAF of a TP53 and U2AF1 mutation from plasma ctDNA was comparable to DNA from PB cytopenias are common in MDS; as such molecular assessment of neutrophils and other peripheral blood cells is not always feasible. Therefore, the current 'gold standard' for molecular testing in MDS is from BM aspirate DNA. Indeed, much of our understanding of the MDS genomic landscape has been through sequencing this compartment 6 . In all cases (n=10), the main driver mutations were detected in both BM and ctDNA (Table 1 ). Importantly, there was an excellent correlation (r 2 =0.84; p<0.0001) between the MAF of these mutations in BM and ctDNA across multiple matched time-points (n=75) ( Figure 1C ). This is the highest correlation reported between a tumour compartment and ctDNA. Importantly, this correlation was preserved even when the patients were leucopenic (Supplemental Figure 1C and 1D) and there was no correlation between ctDNA MAF and peripheral blood white cell count (Supplemental Figure 1E ). Together these data confirm the fact that ctDNA accurately reflects the genomic architecture of bone marrow blasts in MDS regardless of the peripheral blood white cell count. Not infrequently BM biopsies provide poor quality specimens due to technical difficulties such as BM fibrosis or hypoplasia. In situations where a sub-optimal, blood dilute BM aspirate was obtained, ctDNA analysis provided equal, and in some cases superior molecular information to BM sampling ( Figure 1D and supplemental Figure 2 ).
ctDNA dynamics reflect tumor burden during therapy for MDS.
Overall assessment of therapeutic response in MDS is measured using standard criteria 20 . However, these criteria fail to appreciate the tumour heterogeneity in MDS and do not capture the clonal dynamics and evolutionary changes observed with therapeutic pressure. Therefore, to better understand this, serial TS and/or dPCR analysis was performed on BM and ctDNA in the 10 patients with detected mutations (Figure 1 , Supplemental Figure 2 ). In each case, ctDNA dynamics closely followed that of BM DNA.
Studies have shown that TET2 mutations predict response to azacitidine 21, 22 , although benefit appears confined to patients with a MAF >10%. Futhermore, not all clones that harbor TET2 mutations show sensitivity to azacitidine 21 . In case AZA004, there were two TET2 mutations present at baseline with a MAF>10%. Consistent with the findings of Bejar et al. a response to therapy was achieved, which was paralleled by a reduction in the MAF of both TET2 mutations in plasma ctDNA ( Figure 1D ). Importantly, we also found cases with distinct TET2 mutations where the TET2 mutant clones were not suppressed by azacitidine therapy (Supplemental Figure 2E ).
Despite initial response to azacitidine-based therapies, progression invariably occurs. In case AZA009, despite initial clinical stability during treatment, For personal use only. on August 31, 2017. by guest www.bloodjournal.org From ctDNA demonstrated an expanding malignant sub-clone containing the NRAS mutation, which ultimately resulted in the patient's progression to AML ( Figure  1E ). Importantly, in several patients who progressed after an initial response to therapy, ctDNA reflected dynamic changes in tumor burden ( Figure 1F , Figure 1H , Supplemental Figure 2B -F).
Together these findings highlight the ability of ctDNA analysis to mirror the genomic changes observed in the BM and track multiple driver mutations throughout therapy. Importantly, ctDNA shows the differential response of the malignant subclones during therapy and can be used to identify and pre-empt disease progression.
Serial ctDNA analysis can monitor karyotypic abnormalities in plasma.
Although used in MDS prognostic models 2 , the difficulty in using karyotypic abnormalities as a monitoring tool is that they are present in less than 50% of cases 17, 23 . This may be further compounded by lack of sensitivity of metaphase cytogenetics. To address this, we used low-coverage whole genome sequencing (LC-WGS) to monitor chromosomal aberrations in plasma from three MDS patients throughout therapy (Figure 1, Supplemental  Figure 3 ).
Case AZA011 highlights a patient who had a del9q alteration detected in the BM by conventional cytogenetics (28/30 metaphase cells) ( Table 1) . Prior to treatment, this del9q was clearly identifiable in plasma ctDNA ( Figure 1G ). Notably, following clinical response to therapy, the copy number alteration was markedly reduced in plasma, suggesting that azacitidine was able to supress the malignant clone and allow haematopoiesis to be restored from other haematopoietic stem and progenitor cells 24 . The patient achieved a prolonged response (>4 years) but eventually progressed in the BM with an increasing myeloblast count (Day 1492). Interestingly, progression was associated with a re-emergence of the del9q clone, which ctDNA detected almost 3 months before confirmation by BM cytogenetic analysis ( Figure 1G ). Importantly, whilst no cytogenetic evolution was noted at progression, TS clearly showed clonal evolution with the emergence of a new ASXL1 mutation in ctDNA at this time ( Figure 1H ). ASXL1 mutations confer a poor outcome in the myeloid malignancies potentially negating the positive influence of TET2 mutations in mediating response to azacitidine therapy 21, 22 . It is currently unclear if azacitidine primarily acts by supressing or differentiating the dominant malignant clone 11, 25, 26 . Whilst, the data in this case would suggest the former, it remains entirely possible that in other cases azacitidine results in a restoration of blood counts by differentiating the malignant clone.
There is growing evidence supporting the importance of molecular assessment in MDS. Here we show that ctDNA mirrors the genomic information from BM, accurately reflects the dynamic clonal changes seen in response to therapy and can predict treatment failure. Together these data support the use of ctDNA analysis as a non-invasive biomarker to compliment existing monitoring strategies for MDS. This work is also supported by the Klempfner Epigenetics Fellowship administered by the Snowdome Foundation to PY. The clinical study patient recruitment was funded by the Victorian Cancer Agency, Celgene and GlaxoSmithKline. We would like to thank Gisela Mir Arnau, Timothy Semple, Sreeja Gadipally and Timothy Holloway for assistance with low coverage whole genome sequencing, Michelle McBean for assistance with sample retrieval, as well as Meaghan Wall for providing cytogenetic information on patients.
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The authors declare no competing financial interests. (D) Case AZA004 -Serial comparison of the MAF of TET2 N1890I and TET2 D1376V mutation by dPCR between BM and plasma ctDNA. The patient had MDS with a classification of RAEB-2, which responded to azacitidine and eltrombopag therapy by a reduction in BM myeloblast percentage. At various time-points (day 193, day 318 and day 599), poor quality blood dilute aspirate samples were obtained (denoted by *). At these times, plasma ctDNA MAF was higher than BM MAF of the TET2 N1890I and TET2 D1376V mutation. There was also severe neutropenia at these time-points (neutrophils = 0.13, 0.15 and 0.16 x10 9 /L respectively).
(E) Case AZA009 -Serial MAF of a NRAS G13D mutation by dPCR of BM and plasma ctDNA. The patient had RAEB-1 and stable disease after azacitidine and eltrombopag therapy represented by a persistent but stable excess of bone marrow blasts. There was eventual progression at day 407 of therapy to acute myeloid leukemia.
(F) Case AZA007 -Serial MAF of a KRAS A59G and SRSF2 P95H mutation by TS of BM and plasma ctDNA respectively. The patent had RCUD with severe thrombocytopenia, which responded initially to azacitidine and eltrombopag therapy. The patient eventually progressed with an increase in BM myeloblast percentage. Of note, the SRSF2 mutation, despite being reduced, still remained detectable in ctDNA at all time-points sampled. At the time of disease progression, the MAF of the SRSF2 mutation in plasma had clearly increased, whilst the KRAS mutation remained undetectable.
(G) Depth of coverage (DOC) log2 ratio plots from LC-WGS of plasma in patient AZA011. At "baseline" (top panel), the plot shows the presence of a loss of copy number at chromosome 9 (yellow) prior to azacitidine therapy. At "response" on day 167 (middle panel) there is near resolution of the copy number alteration at chromosome 9. At day 1441, whilst still on therapy, at "pre-progression" (bottom panel) there is re-emergence of the loss of copy number at chromosome 9 (yellow). 
